Analytical Data
-
Gene name
PHEMX
- Application
-
Alternative Names
TSPAN32; PHEMX; TSSC6; Tetraspanin-32; Tspan-32; Protein Phemx
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96QS1
-
Expression Region
1-258 aa
-
AA Sequence
MGPWSRVRVAKCQMLVTCFFILLLGLSVATMVTLTYFGAHFAVIRRASLEKNPYQAVHQWAFSAGLSLVGLLTLGAVLSAAATVREAQGLMAGGFLCFSLAFCAQVQVVFWRLHSPTQVEDAMLDTYDLVYEQAMKGTSHVRRQELAAIQDVFLCCGKKSPFSRLGSTEADLCQGEEAAREDCLQGIRSFLRTHQQVASSLTSIGLALTLGPQGQIHPDPTSMWPPAPGAQPLEMLPGWTHTLSPLRSSCYWSKRMLG
-
Molecular Weight
54.12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PHEMX is a recombinant protein that has garnered attention due to its potential applications in therapeutic development, particularly in the fields of infectious diseases and immunotherapy. Research into PHEMX is grounded in the increasing need for novel treatments as traditional approaches face challenges such as antibiotic resistance and the limitations of current vaccines. The protein itself is derived from a specific pathogen, which makes it a compelling candidate for vaccine formulation to elicit robust immune responses. Studies have shown that PHEMX can enhance the presentation of antigens to the immune system, potentially leading to improved vaccine efficacy. Moreover, its unique structural properties enable it to undergo modifications, facilitating the exploration of its use in targeted drug delivery systems. The recombinant nature of PHEMX allows for large-scale production and scalability for clinical applications. As researchers continue to investigate its immunogenic properties and mechanisms of action, the versatility of PHEMX could pave the way for innovative strategies in combating both chronic and emerging infectious diseases, making it a vital subject of study in modern biomedical research.
